Escitalopram in Clinical Practice: Results of an Open-Label Trial in Outpatients with Depression in a Naturalistic Setting in Germany

Abstract

Introduction: An open, multi-center, study was designed to address the efficacy and tolerability profile of treatment with escitalopram under naturalistic conditions in outpatients with depression.

Methods: A total of 11,760 patients were treated with escitalopram and followed for 8 weeks. Rating scales included the Clinical Global Impression-Severity (CGI-S), the Clinical Global Impression-Improvement (CGI-I), and a short version of the Montgomery-Åsberg Depression Rating Scale (svMADRS) for assessment of various clinical parameters.

Results: During the course of the study, patients showed a clear pattern of improvement in their general state of health (CGI-S) and a decrease in the severity of their depression. The majority (82.8%) of patients initially received 10 mg/day escitalopram. By the end of the trial period, 32.5% of the patients were treated with 20 mg/day escitalopram compared to 64.0% receiving 10 mg/day escitalopram. After 2 weeks, 40.7% of patients were much or very much improved (CGI-I ≤2), increasing to 82.5% at the last assessment. There were no significant differences in response to treatment between women and men, with regard to treatment by specialists versus GPs, or with regard to age (≤65 versus >65 years of age). Adverse reactions were similar to those found in controlled trials, and no new reactions were noted. The most common adverse reactions were nausea, anxiety, and vertigo.

Conclusions: This observational study corroborates the high therapeutic efficacy of escitalopram treatment, while confirming the tolerability profile, in a naturalistic treatment setting.

escitalopram - citalopram - major depressive disorder - antidepressants - SSRI - naturalistic - community

References

• 1 Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.  Pharmacopsychiatry. 2006;  39 128-134
• 2 Boulenger JP, Huusom AKT, Florea I, Bækdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.  Curr Med Res Opin. 2006;  22 1331-1341
• 3 Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.  J Clin Psychiatry. 2002;  63 331-336
• 4 Chen F, Larsen MB, Sánchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.  Eur Neuropsychopharmacol. 2005;  15 193-198
• 5 Colonna L, Reines EH, Andersen HF. A randomized,double-blind, 24-week study of escitalopram (10 mg/day)versus citalopram (20 mg/day)in primary care patients with major depressive patients with major depressive disorder.  Curr Med Res Opin. 2005;  21 1659-1668
• 6 Fachinformation zu CIPRALEX^® 10 mg und CIPRALEX^® 20 mg Filmtabletten. Lundbeck GmbH Januar 2004
• 7 Guy W:. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338 1976 Rockville, MD, National Institute of Mental Health
• 8 Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder: a meta-analysis versus selective serotonin reuptake inhibitors and venlafaxine XR.  J Psychiatry Neuroscience. 2006;  31 122-131
• 9 Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.  Pharmacopsychiatry.. 2006;  39 180-184
• 10 Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2003;  18 211-217
• 11 Linden M, Ludewig K, Munz T, Dierkes W. Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: Results of a drug utilization observation study.  Pharmacopsychiatry. 2003;  36 197-205
• 12 Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.  Int Clin Psychopharmacol. 2005;  20 131-137
• 13 Möller HJ, Schnitker J. Einsatz einer modifizierten MADRS bei depressiven Patienten in einer prospektiven Kohortenstudie.  Der Nervenarzt. 2006;  77 ((Suppl 2)) S172-S173
• 14 Pedersen AG. Escitalopram and suicidality in adult depression and anxiety.  Int Clin Psychopharmacol. 2005;  20 139-143
• 15 Rush AJ, Bose A. Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting.  Depress Anxiety. 2005;  21 26-32
• 16 Sánchez C, Bøgesø K, Ebert B, Heldbo Reines E. et al . Escitalopram versus Citalopram: the surprising role of the R-enantiomer.  Psychopharmacology. 2004;  174 163-176
• 17 Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2002;  17 95-102
• 18 Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?.  Am J Psychiatry. 2002;  159 469-473

Correspondence